Camphoric Acid

Camphoric Acid

SCHEMBL12083956

CC1(C)[C@H](C(=O)O)CC[C@@]1(C)C(=O)O

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.66
LMNA P02545 2/20 0.57
POLB P06746 1/20 0.57
NPSR1 Q6W5P4 4/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
HTT P42858 1/20 0.47
TP53 P04637 1/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
CYP1A2 P05177 2/20 0.40
TSHR P16473 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2C9 P11712 1/20 0.40
FFAR3 O14843 1/20 0.37
GRM2 Q14416 2/20 0.35
GRM3 Q14832 2/20 0.35
GRM4 Q14833 2/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Camphoric Acid SCHEMBL12084182 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL2513165 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL30078310 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL23643 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL1738809 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL52395 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL12308 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL7102028 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL7099871 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL27486599 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110305034-B Composition containing camphoric acid derivative and application thereof in cosmetics 佛山市顺德区香江精细化工实业有限公司 2022-06-07 CN disclosed
EP-2685981-B1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2016-08-24 EP disclosed
US-8921368-B2 Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-30 US disclosed
US-20140011795-A1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL-MYERS SQUIBB COMPANY 2014-01-09 US disclosed
US-8258126-B2 Vitamin D3 analogues for the prevention and treatment of bone disorders K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2012-09-04 US disclosed
US-8258126-B2 Vitamin D3 analogues for the prevention and treatment of bone disorders K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2012-09-04 US disclosed
US-20100160455-A1 VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) 2010-06-24 US disclosed
US-20100160455-A1 VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) 2010-06-24 US disclosed
US-7704986-B2 5-(((3-((4-Hydroxy,1,5-dimethylhexyl)-2,2,3-(trimethyl)cyclopentyl)-2-propenylidene)cyclohexane-1,3-diol; induce bone matrix formation; mineralization without hypercalcemia; side effect reduction; bone disorders; osteomalacia, renal osteodystrophy, Paget's disease and osteoporosis; skin disorders K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) 2010-04-27 US disclosed
EP-1809599-B1 VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS LEUVEN K U RES & DEV (BE) 2008-12-10 EP disclosed
US-20080032955-A1 VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160455-A1 VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS VDR, CYP24A1, CYP2R1 ALDH1A1 4226/4885LMNA 531/4885POLB 2845/4885
US-20140011795-A1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES JAK3, JAK1, JAK2 ALDH1A1 2145/4885LMNA 4832/4885POLB 1988/4885
US-20080032955-A1 VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS VDR, CYP24A1, CYP2R1 ALDH1A1 4226/4885LMNA 531/4885POLB 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.